Evidence map›Paper›PMID 40105775›Full record

ArticleDisease models & mechanisms2025

Nonlinear progression during the occult transition establishes cancer lethality.

Joshua D Ginzel, Henry Chapman, Joelle E Sills, Edwin J Allen, Lawrence S Barak, Robert D Cardiff, Alexander D Borowsky, Herbert Kim Lyerly, Bruce W Rogers, Joshua C Snyder

Abstract read
In one paragraph

Article in Disease models & mechanisms, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Precision preclinical modeling to advance cancer treatment.Journal of the National Cancer Institute · 2025
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Joshua D GinzelDepartment of Surgery, Duke University, Durham, NC 27710, USA.ORCID 0000-0001-5635-7314
Henry ChapmanDepartment of Surgery, Duke University, Durham, NC 27710, USA.
Joelle E SillsDepartment of Surgery, Duke University, Durham, NC 27710, USA.
Edwin J AllenDepartment of Surgery, Duke University, Durham, NC 27710, USA.
Lawrence S BarakDepartment of Cell Biology, Duke University, Durham, NC 27710, USA.
Robert D CardiffDepartment of Pathology and Laboratory Medicine, UC Davis, Davis, CA 95817, USA.ORCID 0000-0003-3088-8816
Alexander D BorowskyDepartment of Pathology and Laboratory Medicine, UC Davis, Davis, CA 95817, USA.ORCID 0000-0003-3117-9202
Herbert Kim LyerlyDepartment of Surgery, Duke University, Durham, NC 27710, USA.ORCID 0000-0002-0063-4770
Bruce W RogersDepartment of Surgery, Duke University, Durham, NC 27710, USA.ORCID 0000-0002-4296-7645
Joshua C SnyderDepartment of Surgery, Duke University, Durham, NC 27710, USA.ORCID 0000-0002-9787-3371

Funding

Visualizing tumor heterogeneity in an immune intact and autochthonous mouse model of breast cancerR01CA255372 · NCI · DUKE UNIVERSITY · PI SNYDER, JOSHUA CLAIR · 2021 to 2025
$2.3M
Duke UniversityNCI NIH HHS 1R01CA255372-01NCI NIH HHS R01 CA255372U.S. Department of Defense W81XWH-21-2-0031
6 · The paper itself

Abstract

Cancer screening relies upon a linear model of neoplastic growth and progression. Yet, historical observations suggest that malignant progression is uncoupled from growth, which may explain the paradoxical increase in early-stage breast cancer detection without a dramatic reduction in metastasis. Here, we lineage trace millions of transformed cells and thousands of tumors using a cancer rainbow mouse model of HER2 (also known as ERBB2)-positive breast cancer. Transition rates from field cell to screen-detectable tumor to symptomatic tumor were estimated from a dynamical model of tumor development. Field cells were orders of magnitude less likely to transition to a screen-detectable tumor than the subsequent transition from screen-detectable tumor to symptomatic tumor. Our model supports a critical 'occult' transition in tumor development during which a transformed cell becomes a bona fide neoplasm. Lineage tracing and test by transplantation revealed that nonlinear progression during the occult transition gives rise to nascent lethal cancers at screen detection. Simulations illustrated how occult transition rates are a critical determinant of tumor growth and malignancy. Our data provide direct experimental evidence that cancers can deviate from the predictable linear progression model that is foundational to current screening paradigms.

Indexed as

Disease ProgressionNonlinear DynamicsAnimalsBreast NeoplasmsCell LineageCell Transformation, NeoplasticComputer SimulationErb-b2 Receptor Tyrosine KinasesFemaleHumansMiceModels, BiologicalErb-b2 Receptor Tyrosine KinasesBreast cancerCancer progressionMathematical modelingMouse models of cancerQuantitative biologySystems biology

Identifiers

PMID40105775
PMCPMC11957451

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.